Clinical Assessment of GSK716155 [albiglutide] for Type 2 Diabetes Mellitus -A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK716155 in Japanese Subjects With Type 2 Diabetes Mellitus

Trial Profile

Clinical Assessment of GSK716155 [albiglutide] for Type 2 Diabetes Mellitus -A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK716155 in Japanese Subjects With Type 2 Diabetes Mellitus

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Albiglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Oct 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
    • 09 Jun 2009 This study was published as an abstract in the proceedings of the 69th Annual Scientific Sessions of the American Diabetes Association.
    • 27 Oct 2008 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top